Bvf Partners L. P/Il Purchases 931,556 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) Stock

Repare Therapeutics Inc. (NASDAQ:RPTX) major shareholder Bvf Partners L. P/Il acquired 931,556 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was purchased at an average price of $5.00 per share, for a total transaction of $4,657,780.00. Following the completion of the acquisition, the insider now owns 5,155,739 shares in the company, valued at $25,778,695. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Repare Therapeutics Stock Performance

RPTX stock opened at $5.02 on Friday. Repare Therapeutics Inc. has a 1 year low of $3.08 and a 1 year high of $18.68. The firm has a market cap of $211.49 million, a P/E ratio of -2.17 and a beta of 0.09. The stock has a 50-day simple moving average of $7.15 and a 200-day simple moving average of $9.25.

Institutional Investors Weigh In On Repare Therapeutics

Large investors have recently modified their holdings of the stock. Barclays PLC acquired a new stake in shares of Repare Therapeutics in the second quarter valued at about $36,000. Deutsche Bank AG acquired a new stake in Repare Therapeutics during the 4th quarter valued at approximately $40,000. UBS Group AG grew its stake in Repare Therapeutics by 26.3% during the 3rd quarter. UBS Group AG now owns 3,551 shares of the company’s stock valued at $43,000 after purchasing an additional 739 shares in the last quarter. Wells Fargo & Company MN grew its stake in Repare Therapeutics by 185.8% during the 4th quarter. Wells Fargo & Company MN now owns 3,041 shares of the company’s stock valued at $45,000 after purchasing an additional 1,977 shares in the last quarter. Finally, SRS Capital Advisors Inc. acquired a new stake in Repare Therapeutics during the 1st quarter valued at approximately $49,000. Institutional investors and hedge funds own 85.09% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. HC Wainwright cut their price objective on Repare Therapeutics from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, August 17th. Stifel Nicolaus raised their price objective on Repare Therapeutics from $16.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, September 25th. Finally, Piper Sandler lowered their target price on Repare Therapeutics from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, October 16th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Repare Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $21.80.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.